脳動脈瘤に対する局所的遺伝子治療法の開発-実験的検討-

脑动脉瘤局部基因治疗的进展 - 实验研究 -

• 批准号: 16659377
• 负责人: 大熊 洋揮
• 金额: $ 2.05万
• 依托单位: Hirosaki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Exploratory Research
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16659377/
• 关键词: 脳動脈瘤; fibroblast growth factor; platelet derived growth factor; Platelet derived growth factor

脳動脈瘤の遺伝子治療という観点からウサギ脳動脈瘤発生モデルを用い、脳動脈瘤作製処置後6ヶ月後に脳動脈瘤の発生を確認できた動物に関し種々遺伝子の導入を行い動脈瘤の縮小化が得られるかを検討することが目的である.Basic fibroblast growth factor, platelet derived growth factor遺伝子をハイドロゲル・ポリマーに包含させ,これを手術用顕微鏡下で脳動脈瘤壁に塗布し,遺伝子導入を図り、3,6ヶ月後に脳動脈を摘出し、mRNAレベルをreverse transcription-polymerase chain reaction(RT-PCR)で定量的に分析し、蛋白質レベルを免疫染色法で定性的に分析した。さらに脳動脈瘤の縮小が得られるかどうかを組織学的に検討した.対照として治療処置を受けない群と比較を行った.3ヶ月後の変化としては,mRNAレベルはBasic fibroblast growth factor, platelet derived groth-factorともに有意な発現が見られ,免疫染色法による蛋白質レベルの検討でも両蛋白の血管壁における染色性の増強が主に中膜外層〜外膜に観察された.内膜〜内膜下には染色性は認められなかった.この時点での脳動脈瘤のサイズは対照群に比し,治療群では径として75%への縮小がみられ,かつ脳動脈瘤の壁が160%への増大が観察された.従って,これらの遺伝子の導入は脳動脈瘤の治療に応用出来る可能性があると考えられた.

Six months after the operation of the tumor, it was confirmed that all kinds of animal products were introduced into the tumor. The purpose of the Basic fibroblast growth factor is to reduce the size of the tumor. The platelet derived growth factor slides were scanned by microscopes, and the tumor walls were scraped with microscopes. The slides were inserted into the tumours, and 6 months later, the slides were extracted, mRNA scans were quantitatively analyzed by reverse transcription-polymerase chain reaction (RT-PCR), and the proteins were analyzed qualitatively by immunostaining. You can get a lot of information about how to make sure that you don't know how to do this. After 3 months of treatment, the patients were treated with mRNA, Basic fibroblast growth factor, platelet derived groth-factor, and immunostaining was used to detect the expression of protein in the vascular wall. The intima to the intima is stained. At different times, we will compare the results of each group of people, 75% of the time, 75% of the time, and 160% of the time. The possibility that you can use it in the treatment of cancer.